Effect of recombinant human nerve growth factor treatment on corneal nerve regeneration in patients with neurotrophic keratopathy

A Balbuena-Pareja, CS Bogen, SM Cox… - Frontiers in …, 2023 - frontiersin.org
Introduction Neurotrophic Keratopathy (NK) is a neurodegenerative corneal disease that
results in diminished corneal sensation. Previous studies have found that Cenegermin …

In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy

L Mastropasqua, M Lanzini, HS Dua, A D'Uffizi… - American journal of …, 2020 - Elsevier
Purpose To evaluate the renewal of corneal nerve structure and function in patients with
neurotrophic keratopathy (NK) treated with recombinant human nerve growth factor (rhNGF) …

Cutting Edge: Topical Recombinant Nerve Growth Factor for the Treatment of Neurotrophic Keratopathy—Biologicals as a Novel Therapy for Neurotrophic Keratopathy

P Hamrah, LY Saricay, MC Ozmen - Cornea, 2022 - journals.lww.com
Ophthalmologists find management of neurotrophic keratopathy (NK) challenging because
conventional therapy lacks efficacy and may result in permanent loss of vision. Recombinant …

Efficacy and tolerability of cenegermin for stage 1 neurotrophic keratopathy

LY Saricay, B Bayraktutar, J Lilley… - … & Visual Science, 2020 - iovs.arvojournals.org
Purpose: Topical recombinant human nerve growth factor (rhNGF, cenegermin-bkbj,
Oxervate 0.002%, Dompé US Inc) has been approved by FDA in all stages of neurotrophic …

Efficacy of recombinant human nerve growth factor in stage 1 neurotrophic keratopathy

LY Saricay, BN Bayraktutar, J Lilley, FS Mah… - …, 2022 - aaojournal.org
Neurotrophic keratopathy (NK) is a vision-threatening condition that results from injury or
dysfunction of corneal nerves and subsequent decrease or loss of corneal sensation. 1 …

[HTML][HTML] Clinical observation of recombinant human nerve growth factor in the treatment of neurotrophic keratitis

M Hao, Y Cheng, J Wu, Y Cheng… - International Journal of …, 2023 - ncbi.nlm.nih.gov
AIM To characterize changes of corneal nerve morphology and tear indices in patients with
neurotrophic keratitis (NK) treated with recombinant human nerve growth factor (rhNGF) …

Long-term clinical efficacy of topical treatment with recombinant human nerve growth factor in neurotrophic keratopathy: a novel cure for a rare degenerative corneal …

A Bruscolini, M Marenco, GM Albanese… - Orphanet Journal of …, 2022 - Springer
Background Neurotrophic keratopathy (NK) is a rare, degenerative ocular disease
characterized by reduction or loss of corneal sensitivity and development of non-healing …

Eight months follow-up of corneal nerves and sensitivity after treatment with cenegermin for neurotrophic keratopathy

E Pedrotti, E Bonacci, C Chierego… - Orphanet Journal of …, 2022 - Springer
Abstract Backgroud Cenegermin (Oxervate, Dompè Farmaceutici, Milan, IT), a recombinant
human NGF, is a potentially healing new drug for neurotrophic keratopathy (NK), a rare but …

[HTML][HTML] Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial

SC Pflugfelder, M Massaro-Giordano, VL Perez… - Ophthalmology, 2020 - Elsevier
Purpose To evaluate the efficacy and safety of topical cenegermin (recombinant human
nerve growth factor) in patients with neurotrophic keratopathy. Design Multicenter …

[HTML][HTML] Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis

S Bonini, A Lambiase, P Rama, F Sinigaglia… - Ophthalmology, 2018 - Elsevier
Purpose To evaluate the safety and efficacy of topical recombinant human nerve growth
factor (rhNGF) for treating moderate-to-severe neurotrophic keratitis (NK), a rare …